Purple Biotech says USPTO issues notice of allowance for CAPTN-3 tri-specific antibody patent application
PPBT•Patent protection for new antibody candidates
Patent protection targets faster development of new antibody candidates by swapping tumor-associated antigen binding domains on a common architecture.
USPTO allowance for CAPTN-3 patent application
Purple Biotech received a USPTO Notice of Allowance for a U.S. patent application covering tri-specific antibody constructs and methods of use.
The allowance expands IP protection for the CAPTN-3 platform, a modular backbone for conditionally activated multispecific antibodies.
